India Morning Newsletter, April 29-June 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

India Morning Newsletter, April 29

Apr 28, 2024 8:23 PM

To access a PDF version of this newsletter, please click here

If you would like to receive this newsletter via email, please register at:

https://solutions.refinitiv.com/MNCIndiaSubscriptionpage

For an index of our newsletters click on

Previous page： Sangamo's Cash on Balance Sheet Seen as 'Overhang' as Pfizer Pulls Out of Hemophilia A Therapy Study, Truist Says Next page： Merck wins UK approval for lung disease drug acquired in $11 bln deal

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sangamo's Cash on Balance Sheet Seen as 'Overhang' as Pfizer Pulls Out of Hemophilia A Therapy Study, Truist Says

Dec 31, 2024

08:41 AM EST, 12/31/2024 (MT Newswires) -- Sangamo Therapeutics' ( SGMO ) cash on its balance sheet remains an overhang following Pfizer's ( PFE ) decision to terminate a hemophilia A gene therapy collaboration with the company, Truist Securities said in a Monday note. The partnership and license agreement between the two companies are anticipated to close in Q1 next...

Merck wins UK approval for lung disease drug acquired in $11 bln deal

Dec 31, 2024

Dec 31 (Reuters) - UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's ( MRK ) therapy to treat a rare lung condition, marking another win for the drugmaker's potential blockbuster. The therapy, sotatercept, received U.S. approval in March 2024 and is sold under the brand name Winrevair. It is also approved in European Union...

Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025

Dec 31, 2024

08:38 AM EST, 12/31/2024 (MT Newswires) -- Drugmakers including Pfizer ( PFE ) , Bristol-Myers Squibb ( BMY ) and Sanofi ( SNY ) plan to raise US list prices on at least 250 branded medications, including COVID-19 treatments, cancer cell therapies and vaccines, at the start of 2025, Reuters reported Tuesday, citing data from the healthcare research firm 3...

Kazia Therapeutics Shares Drop After FDA Derails Fast Track of Potential Brain Cancer Drug

Dec 31, 2024

08:44 AM EST, 12/31/2024 (MT Newswires) -- Kazia Therapeutics ( KZIA ) shares fell more than 6% in pre-market trading Tuesday after the company said it was considering options for its drug candidate paxalisib after the US Food and Drug Administration discouraged an accelerated approval process for the potential glioblastoma treatment. The company said a July study of the drug...